Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Declines By 23.7%

iSpecimen Inc. (NASDAQ:ISPC) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 29,600 shares, a decrease of 23.7% from the January 31st total of 38,800 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily volume of 883,000 shares, the short-interest ratio is currently 0.0 days.

iSpecimen Price Performance

Shares of NASDAQ ISPC opened at $1.54 on Tuesday. The company’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $3.04. iSpecimen has a fifty-two week low of $1.54 and a fifty-two week high of $11.80. The firm has a market capitalization of $1.48 million, a P/E ratio of -0.08 and a beta of 1.63.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Bridgeway Capital Management LLC purchased a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned approximately 2.27% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is owned by institutional investors.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.